Celgene Corporation


Biotech Beat: Analysts Weigh in on Valeant Pharmaceuticals Intl Inc (VRX) and Celgene Corporation (CELG)

Valeant Pharmaceuticals Intl Inc Wells Fargo analyst David Maris is out today with another bearish note on Valeant Pharmaceuticals Intl Inc (NYSE:VRX). In this episode, …

Stock Update (NASDAQ:CELG): Celgene Corporation and Agios Announce Collaborations with Abbott for Diagnostic Identification of IDH Mutations in AML

Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced each company has entered into collaboration agreements with Abbott (NYSE:ABT) to develop and commercialize …

Stock Update (NASDAQ:CELG): Celgene Corporation Announces ABRAXANE Data Presentation at ESMO 2016 Congress

Celgene Corporation (NASDAQ:CELG) announced results from multiple sponsored and independent studies will be presented during the European Society of Medical Oncology (ESMO) 2016 Annual …

Company Update (NASDAQ:CELG): Celgene Corporation Announces Acceptance of Late Breaking GED-0301 CD-001 Abstract at the UEGW Meeting

Celgene Corporation (NASDAQ:CELG) announced that the data from a randomized, double-blind, multicenter, exploratory phase Ib study evaluating the effects of oral GED-0301 (mongersen) …

Piper Jaffray Impressed with Celgene Corporation (CELG) Following Analyst Event

Yesterday afternoon, Celgene Corporation (NASDAQ:CELG) hosted an analyst event with special attention to protein homeostasis. On the heels of the event, Piper Jaffray analyst …

Morgan Stanley Provides a Glimpse into its Global Healthcare Conference: Gilead Sciences, Inc. (GILD), Biogen Inc (BIIB), Celgene Corporation (CELG)

Last week, representatives from some of the largest healthcare companies in the world flocked to New York City to participate in Morgan Stanley’s …

Company Update (NASDAQ:CELG): Celgene Reports Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial at 32nd ECTRIMS

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), announced results from the 96-week blinded extension period (for a total of up …

Cowen Remains Positive on Celgene Corporation (CELG) Following Phase 1B Endoscopy Data

Cowen top analyst Eric Schmidt is out with his commentary on shares of Celgene Corporation (NASDAQ:CELG) after the biotech giant released preliminary data …

Company Update (NASDAQ:CELG): Celgene Corporation Announces Interim Topline Data from Trial of Investigational Oral GED-0301 in Patients with Active Crohn’s Disease

Celgene Corporation (NASDAQ:CELG) announced interim topline data from a randomized, double-blind, multicenter, exploratory phase 1b study evaluating the effects of oral GED-0301 (mongersen) on …

Morgan Stanley Dives in on Celgene Corporation (CELG) Following Physician Expert Lunch

Morgan Stanley analyst Matthew Harrison is out with a research note on shares of Celgene Corporation (NASDAQ:CELG) on the heels of hosting a lunch …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts